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Summary
Cyclin D1 is a multifunctional protein that activates CDK4 and CDK6, titrates Cip/Kip CDK inhibitors to increase CDK2 ac-
tivity, andmodulates the function of certain transcription factors. To specifically test the importance of cyclin D1-associated
kinase activity, we generated ‘‘knockin’’ mice expressing mutant cyclin D1 deficient in activating CDK4/6. The development
of several cyclin D1-dependent compartments, including mammary glands, proceeds relatively normally in these animals,
demonstrating that cyclin D1-associated kinase activity is largely dispensable for development of these tissues. Strikingly,
knockin mice were resistant to breast cancers initiated by ErbB-2. These results demonstrate a differential requirement for
cyclin D1-CDK4/6 kinase activity in development versus tumorigenesis and strongly support cyclin D1-dependent kinase
activity as a specific therapeutic target in breast cancer.Introduction
The family of D-type cyclins (D1, D2, and D3) are important reg-
ulators of the G1-S phase transition (Sherr, 1995). Aberrant over-
expression of the D cyclins, and cyclin D1 in particular, has been
linked to loss of cell cycle control and awide variety ofmalignan-
cies. Of notable importance, the cyclin D1 gene is amplified in
w20% of breast cancers, and the cyclin D1 protein is overex-
pressed in greater than 50% of cases (Donnellan and Chetty,
1998). Genetic models in mice have further emphasized the im-
portance of cyclin D1 in both development and tumorigenesis
(Fantl et al., 1995; Sicinski et al., 1995). cyclin D12/2 mice are
about 50% smaller than their wild-type littermates and show
a low frequency of early lethality at about 1 month of age. These
mice exhibit a ‘‘clasping’’ phenotype, wherein the mouse clasps
its rear limbs together, rather than splaying them outward, when
it is lifted by the tail. In addition, a limited number of tissue-
specific defects are observed, including profound hypoplasia
in the retina and a defect in the ability of the mammaryCANCER CELL 9, 13–22, JANUARY 2006 ª2006 ELSEVIER INC. DOI 10.epithelium to proliferate and form lobuloalveolae in response
to hormonal signals during pregnancy.
Interestingly, further analysis of the developing neural retina
by in situ hybridization indicated that cyclin D1 was the only
D-type cyclin whose mRNA was expressed in this tissue at
any appreciable level (Fantl et al., 1995; Sicinski et al., 1995).
This observation suggested that the lack of cyclin D1 might
have a profound effect during retinal development because no
other D cyclin is available in this tissue. Extending this line of
thought led to the hypothesis that the D cyclins may serve re-
dundant and overlapping roles inmost tissues, and that a limited
subset of tissues that express only one D-type cyclin may be af-
fected by the loss of that cyclin. Indeed, mice expressing only
cyclin D3 have a profound defect in cerebellar development,
having a reduced number of folia, decreased cellularity of the in-
ner granular cell layer, and an abnormal Purkinje cell layer (Cie-
merych et al., 2002). Interestingly, molecular analysis of the
granular neuron precursors showed that the N-myc transcrip-
tion factor is upstream of cyclins D1 and D2, but not D3, inS I G N I F I C A N C E
Normal cell proliferation is driven by complexes of cyclins and cyclin-dependent kinases (CDKs) acting at each cell cycle transition
when conditions are appropriate. Altered expression of cyclins can drive aberrant proliferation in cancer. Cyclin D1 is of particular im-
portance, as its expression is increased in many cancers, most notably breast cancer. Mice lacking cyclin D1 fail to develop lactating
mammary glands andare protected from ErbB-2-induced tumors. Using a knockinmousemodel, we show here that activation of CDKs
by cyclin D1 is largely dispensable for development of certain tissues, includingmammary gland, but is required for ErbB-2-dependent
mammary tumors in mice. These data indicate that inhibition of cyclin D1-dependent CDKs could specifically inhibit mammary tumor
cell proliferation.1016/j.ccr.2005.12.019 13
A R T I C L Ethis tissue. This may explain the cerebellar defect in cyclin
D3-only mice: because of dependence on a specific transcrip-
tion factor that activates only cyclins D1 and D2, the cerebellum
is not able to upregulate cyclin D3 to compensate for the loss of
cyclins D1 and D2.
In addition to revealing critical functions in development, sev-
eral models have described the importance of cyclin D1 in
mouse tumors. Expression of cyclin D1 in the mouse mammary
gland under the control of the mouse mammary tumor virus
(MMTV) promoter resulted in deregulated proliferation and the
eventual formation of mammary adenocarcinomas that ex-
pressed high levels of cyclin D1 protein (Wang et al., 1994). Sev-
eral other reports highlight the role of cyclin D1 as a critical
downstream target of other oncogenes. For example, in three
models of oncogenic ras-induced skin tumors, deficiency of
cyclin D1 led to increased latency and decreased penetrance
of tumor formation. These results indicate that cyclin D1 is a pre-
ferred downstream effector of oncogenic ras signaling in these
models (Robles et al., 1998). In addition, cyclin D1 has been
shown to be a critical downstream target inmammary tumors in-
duced by MMTV-ras and MMTV-ErbB-2 (Lee et al., 2000; Yu
et al., 2001). WhereasMMTV-ras andMMTV-ErbB-2 transgenic
mice succumb to mammary gland tumors between 6 months
and 1 year with virtually 100% penetrance, their MMTV-ras;
cyclin D12/2 and MMTV-ErbB-2;cyclin D12/2 littermates are
completely resistant to tumor formation (Yu et al., 2001). These
results indicate that cyclin D1 is a necessary target of the ras and
ErbB-2 oncogenes in mammary tumor formation in the mouse.
The critical role of cyclin D1 in development and tumorigene-
sis may be the result of the ability of D cyclins to bind and acti-
vate cyclin-dependent kinases CDK4 and CDK6; these holoen-
zymes in turn phosphorylate the retinoblastoma protein (pRB)
(Bates et al., 1994; Matsushime et al., 1992; Meyerson and Har-
low, 1994). Surprisingly, very few additional substrates of cyclin
D-CDK4/6 holoenzymes have been identified. However, in addi-
tion to activating the kinase activity of CDK4 and CDK6, D cy-
clins have a number of activities that either do not depend on
the catalytic activity of the partner kinase or do not depend at
all on the partner kinase. Thus, cyclin D1-CDK4/6 complexes
are able to activate cyclin E-CDK2 complexes by titration of
the CDK inhibitors p21Cip1 and p27Kip1 (Cheng et al., 1998; Pol-
yak et al., 1994; Reynisdottir et al., 1995). This kinase-indepen-
dent function has been postulated by some to represent thema-
jor role of cyclin D-CDK4/6 complexes in cell cycle progression
(Geng et al., 2001; Tsutsui et al., 1999). In addition, D cyclins can
interact with and modulate the activity of a number of transcrip-
tion factors in a CDK4/6-independent manner (Bienvenu et al.,
2001; Fu et al., 2004; Inoue and Sherr, 1998; Knudsen et al.,
1999; Neuman et al., 1997; Ratineau et al., 2002; Zwijsen
et al., 1997). A major, unresolved issue is the contribution of
these various ‘‘kinase-dependent’’ and ‘‘kinase-independent’’
functions of D cyclins to development and tumorigenesis.
To address this question, we took advantage of a cyclin D1
point mutant, cyclin D1 K112E, which contains a lysine to gluta-
mine substitution at amino acid position 112. This well-charac-
terized mutant has been previously shown to bind to CDK4
and CDK6 with similar affinity to wild-type cyclin D1, but it is un-
able to activate the catalytic activity of the partner kinase or
transform primary rodent cells (Baker et al., 2005; Hinds et al.,
1994). Importantly, this ‘‘kinase-deficient’’ cyclin D1, when
bound to CDK4/6, is expected to normally titrate p21Cip1 and14p27Kip1, thereby activating cyclin E-CDK2 complexes. More-
over, cyclin D1 K112E and a similarly acting K114E mutant
have been shown to normally interact with and modulate the
activity of various transcription factors (Bienvenu et al., 2001;
Inoue and Sherr, 1998; Knudsen et al., 1999; Neuman et al.,
1997; Ratineau et al., 2002; Zwijsen et al., 1997). By introducing
K112E into the mouse germline, we show here that activation of
CDK4 and/or CDK6 is required for the normal development of
some tissues but not others. Notably, retina and mammary
gland development are nearly normal in these animals. Never-
theless, like animals lacking cyclin D1 altogether, K112E animals
are protected from development of mammary tumors instigated
by the ErbB-2 oncogene. Thus, a requirement for CDK activation
by cyclin D1 is tumor specific in the mammary gland and could
be an excellent therapeutic target.
Results and discussion
Generation of cyclin D1KE/KE knockin mice
We used homologous recombination in embryonal stem (ES)
cells to replace the wild-type cyclin D1 gene with a point mutant
cyclin D1 allele encoding cyclin D1 K112E protein (Figure 1A).
Subsequently, homozygous ‘‘knockin’’ mice expressing cyclin
D1 K112E were generated using standard procedures; these
mice will be hereafter referred to as cyclin D1KE/KE animals.
The tissues of homozygous cyclin D1KE/KE mice are expected
to express ‘‘kinase-deficient’’ cyclin D1-CDK4 and cyclin D1-
CDK6 complexes. Importantly, the structure of the recombined
allele is expected to preserve normal regulation of expression.
The cyclin D1KE/KEmice were born in a normal Mendelian ratio
(data not shown). We confirmed the presence of the desired
point mutation in the genomes of these mice by DNA sequenc-
ing (Figure 1C). To determine whether the KE allele was
expressed in a normal manner, we analyzed the levels of cyclin
D1 or cyclin D1 KE protein in the tissues of adult cyclin D1KE/KE
mice and their wild-type littermates. These analyses demon-
strated normal levels of the knockin protein in all organs exam-
ined (hearts, lungs, spleens, livers, and kidneys) (Figure 1D); we
noted, however, that the slower-migrating cyclin D1 species
was less abundant in the mutant tissues. Although we have
not determined the origin of the two forms of cyclin D1 in these
tissues, it has previously been reported that cell cycle-depen-
dent cyclin-CDK complex formation results in phosphorylation
of cyclin D1 at T286; this produces a slowermigrating form (Mat-
sushime et al., 1994; Diehl et al., 1997). We also verified normal
expression levels of cyclins D2 and D3, CDK4, CDK6, and
p27Kip1 in cyclin D1KE/KE animals (Figures 1E and 1F). We con-
clude that the introduction of a point mutation into the endoge-
nous cyclin D1 locus did not affect overall cyclin D1 levels and
did not perturb the expression of other cell cycle regulators.
Hence, cyclin D1KE/KEmice offer us a tool to address the require-
ment for cyclin D1-CDK4/6 kinase function in development and
in carcinogenesis.
Retinal development and function in cyclin
D1KE/KE knockin mice
We observed cyclin D1KE/KE mice throughout their lives and
compared their appearance with that of mice lacking cyclin
D1. As reported previously, cyclin D1 null mice display severelyCANCER CELL JANUARY 2006
A R T I C L Ehypoplastic retinas, with all neuronal cell layers (outer nuclear,
inner nuclear, and ganglion cell) being profoundly affected (Fantl
et al., 1995; Sicinski et al., 1995) (Figure 2A). This indicates that
cyclin D1 function is critically required for retinal development.
Strikingly, we found that the retinas of the homozygous cyclin
D1KE/KE animals developed relatively normally, being only
slightly underdeveloped in comparison to retinas from wild-
type littermates (Figure 2A). To obtain a quantitative measure
of retinal function in cyclin D1KE/KE mice, we performed electro-
retinographic analyses. These studies demonstrated that the
retinas of cyclin D1KE/KEmice responded to light with electroret-
inographic potentials corresponding to approximately 65% of
those seen in wild-type mice. In contrast, cyclin D1 null mice re-
spond at 10% of wild-type levels (Figure 2B). We conclude that,
while cyclin D1 function is clearly required for retinal develop-
ment, kinase activity associated with cyclin D1 is largely dis-
pensable for this process.
Unlike many other tissues, which express two or even all three
D-typecyclins, thedeveloping retinaexpressesmainly cyclinD1.
For this reason,weused retinas derived from cyclinD1KE/KEmice
to analyze the properties of the KE protein without interference
from other D cyclins. First, we examined the expression of vari-
ous cell cycle regulators in the lysates of retinas microdissected
from 1-day-old pups (Figure 2C). We found that the levels of
cyclin D1 KE in the retinas of knockin mice closely resembled
the levels of cyclin D1 seen in the retinas of wild-type littermates.
As was the case in other tissues (see Figure 1D), we observed
that, in the knockin retinas, the faster migrating species of cyclin
D1 was more abundant than the slower migrating form (Fig-
ure 2C). We also observed slightly decreased levels of CDK4
and p27Kip1 in the mutant retinas (Figure 2C).
To verify that cyclin D1 KE-CDK4 complexes retain the ability
to titrate p27Kip1, we immunoprecipitated CDK4 from the retinal
lysates and probed the immunoblots with antibodies against cy-
clin D1 and p27Kip1. Of relevance here is data demonstrating that
free (uncomplexed with D cyclins) CDK4 is unable to bind
p27Kip1 (Hall et al., 1995; Kozar et al., 2004), and that the kinase
activity of CDK4 is not required for the formation of cyclin D1-
CDK4-p27Kip1 complexes (Baker et al., 2005). Consistent with
these data, we observed that cyclin D1 KE-CDK4 complexes re-
tained the ability to bind p27Kip1 (Figure 2D). Although less CDK4
was immunoprecipitated from the cyclin D1KE/KE lysates, as
might be expected due to the decreased CDK4 expression in
the knockin retinas, the relative amounts of cyclin D1 KE protein
and p27Kip1 that coimmunoprecipitated with CDK4 were similar
in thewild-type and cyclin D1KE/KE lysates. As expected, virtually
no p27Kip1 coimmunoprecipitated with CDK4 from cyclin D12/2
retinas, confirming the requirement for cyclin D1 in p27Kip1 titra-
tion (Figure 2D).
To determine whether titration of p27Kip1 by cyclin D1 KE-
CDK4 complexes resulted in activation of CDK2, we performed
in vitro kinase assays to measure CDK2 activity. These analyses
demonstrated nearly normal CDK2-associated kinase activity in
the retinas of the knockin mice (Figure 2E). We conclude that cy-
clin D1 KE-CDK4 complexes at least partially retain the ability to
activate CDK2 by titrating p27Kip1. In contrast, cyclin D12/2 ret-
inas lack cyclin D1-CDK4 complexes and are thus unable to ti-
trate p27Kip1 (Figure 2D). As a consequence, CDK2-associated
kinase activity is not activated in a normal manner in cyclin D1
null retinas (Figure 2E); these retinas are therefore deficient in
both CDK4- and CDK2-dependent kinase activity. However,CANCER CELL JANUARY 2006this simple picture is complicated by the observation that KE ret-
ina lysates contain elevated levels of cyclin E and slightly re-
duced levels of the fast-migrating, active form of CDK2. These
data suggest that the effects of cyclin D1 KE expression on
CDK2 activity are complex. The observed CDK2 activity likely
not only results from p27Kip1 titration by cyclin D1 KE-CDK4
complexes, but may also depend on reduced steady-state lev-
els of p27Kip1. The mechanisms underlying p27Kip1 homeostasis
in the retina are currently unclear; however, the above-
describedmultiplicity of effects resulting from alteration of cyclin
D1 presumably reflects complex crosstalk among several im-
portant cell cycle regulatory proteins.
We next examined the phosphorylation status of the retino-
blastoma protein (pRB), which represents a target of cyclin
D-CDK4/6, cyclin E-CDK2, and cyclin A-CDK2 complexes.
Probing of immunoblots with an antibody recognizing all of the
phospho-forms of the retinoblastoma protein demonstrated
that the fraction of hyperphosphorylated, slower-migrating
pRB was dramatically reduced in the retinas of knockin mice
(Figure 2F). The residual levels of pRB phosphorylation seen in
cyclin D1KE/KE retinas are likely contributed by cyclin E-CDK2
kinase. In contrast, the absence of cyclin D1-CDK4 complexes
in cyclin D1 null retinas cripples both cyclin D1-CDK4 and cyclin
E-CDK2 kinases, leading to even more severe impairment of
pRB phosphorylation (Figure 2F).
To carry this analysis further, we utilized a phospho-specific
antibody to examine the phosphorylation of pRB at the serine
780 (S780) residue, which is thought to be preferentially phos-
phorylated by cyclin D-associated kinase activity (Kitagawa
et al., 1996), and also less efficiently by CDK2-containing com-
plexes (Kozar et al., 2004) (Figure 2F). We found that the phos-
phorylation of pRB at S780 was severely compromised in the
cyclin D1KE/KE retinas, as compared to wild-type tissues. The
residual phosphorylation at this site in cyclin D1KE/KE tissues is
likely contributed by CDK2-associated kinase. Consistent with
this thinking, even lower levels of S780 phosphorylation were
observed in cyclin D1 null retinas (Figure 2F). Thus, in agreement
with previous studies of the cyclin D1 K112E mutant (Baker
et al., 2005), the kinase activity of cyclin D1-CDK4/6 complexes
is severely crippled in cyclin D1KE/KE tissues.
Mammary gland development in cyclin D1KE/KE mice
We next turned our attention tomammary gland development. A
critical requirement for cyclin D1 function in this compartment
was previously demonstrated by the observation that mice lack-
ing cyclin D1 fail to undergo themassive mammary epithelial ex-
pansion that normally takes place during pregnancy (Fantl et al.,
1995; Sicinski et al., 1995). As a consequence, cyclin D12/2
females are unable to nurse their pups. In striking contrast, ana-
lyses of cyclin D1KE/KE females demonstrated normal mammary
epithelial expansion, which was indistinguishable from that seen
in wild-type counterparts (Figures 3A and 3B). At the end of
pregnancy, cyclin D1KE/KE females presented fully developed
mammary epithelial trees (Figure 3A). In addition, hematoxylin
and eosin staining of mammary gland sections demonstrated
that mammary glands from cyclin D1KE/KE females are able to
lactate, as indicated by the presence of alveoli containing milk
proteins (Figure 3B). These results indicate that, as was the
case with retinal development, the kinase activity of cyclin D1-
containing complexes is dispensable for breast development.15
A R T I C L EFigure 1. Targeted replacement of the wild-type cyclin D1 gene with the KE allele
A: Schematic diagram of the endogenous cyclin D1 locus and the targeting vector used to engineer embryonal stem (ES) cells by homologous recombina-
tion. This vector contains a point mutation in exon II that changes lysine at amino acid position 112 to glutamine (K112E). In addition, a second, closely linked
silent mutation was introduced that generates a novel PmlI restriction endonuclease site. The coding exons are marked as black boxes and are numbered.
Restriction enzyme sites are also indicated (H, HinDIII; M, MfeI; R, EcoRI; X, XbaI; Xh, XhoI). Probes P1 and P2 were used to screen ES cells for homologous re-
combination by Southern blotting (data not shown).
B: PCR strategy used to genotype the animals. The region surrounding the K112E mutation was amplified by PCR and digested with PmlI (the PmlI site is indi-
cated as P). An undigested 300 bp fragment is produced from the wild-type allele, while the amplification product from the KE allele is digested into 200 bp
and 100 bp fragments. PCR was performed on DNA isolated from tail biopsies; results from wild-type (+/+), cyclin D1KE/+ (KE/+), and cyclin D1KE/KE (KE/KE) ani-
mals are shown.16 CANCER CELL JANUARY 2006
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In addition to these well-defined retinal and mammary epithe-
lial phenotypes, cyclin D1 null mice were reported to show
a set of symptoms that suggests the presence of a develop-
mental neurological abnormality (Fantl et al., 1995; Sicinski
et al., 1995). Thus, cyclin D1 null mice display growth retarda-
tion and a spastic ‘‘leg-clasping’’ reflex and show increased
premature mortality. Analyses of the knockin mice demon-
strated that cyclin D1KE/KE mice retained some, but not all, of
these phenotypic abnormalities. Like cyclin D1 null mice, cyclin
D1KE/KE animals exhibited the pathological ‘‘leg-clasping’’ phe-
notype (Figure 4A). Knockin mice also displayed retarded
growth (Figure 4B). The body mass of 18-day-old male cyclin
D1KE/KE mice represented 61% of that seen in their wild-type
littermates (Figure 4C). In comparison, cyclin D1 null males
had body weights reduced to approximately 50% of normal.
Long-term observation of the cyclin D1KE/KE mice suggests
that this growth deficiency persists throughout life. On the
other hand, we never observed premature mortality of the
‘‘knockin’’ mice, whereas approximately 25% of cyclin D1
null mice died during the first month of life. Altogether, we con-
clude cyclin D1-associated kinase activity is required for some,
but not all, aspects of neurological development. However, the
pathological lesions underlying these presumed neurological
abnormalities have not been defined; hence, we could not
study them further.
One defined compartment in which cyclin D1 is known to
play a role in neurological development is represented by the
cerebellum. Although cyclin D1-deficient mice were shown to
display normal cerebellar development, and this development
was very mildly affected in animals lacking cyclin D2, the
combined ablation of cyclins D1 and D2 led to a very severe
cerebellar hypoplasia (Ciemerych et al., 2002). cyclin D12/2;
cyclin D22/2 cerebella displayed a profound reduction in the
number of cells in the inner granular layer, abnormal layering
of Purkinje cells, abnormal numbers of folia, and low bromo-
deoxyuridine incorporation in the proliferative external granular
layer (Ciemerych et al., 2002). These observations suggest
that cyclins D1 and D2 play redundant, overlapping roles in
driving cerebellar development (cyclin D3 is not expressed in
this organ).
To test whether cyclin D1-associated kinase activity is re-
quired in cerebellar development, we crossed cyclin D1KE/KE
mice with cyclin D2-deficient mice and generated cyclin
D1KE/KE;cyclin D22/2 animals. We found that cyclin D1KE/KE;cy-
clin D2
2/2
mice displayed severely retarded cerebellar develop-
ment (Figures 5A and 5B) that resembled the lesions seen in
mice lacking cyclins D1 and D2. We interpret these results
as an indication that the kinase activity of cyclin D1-containing
complexes plays a role in driving cerebellar development.
Collectively, our analyses of cyclin D1KE/KE mice have dem-
onstrated that the kinase activity of cyclin D1-CDK4/6 is largely
dispensable for the development of some cyclin D1-dependent
compartments (retinas, mammary glands) but is required forCANCER CELL JANUARY 2006development of selected compartments of the nervous
system.
Mammary tumorigenesis in mice expressing ErbB-2
In addition to these developmental abnormalities, cyclin D1-
deficient females were observed to be resistant to mammary
carcinomas initiated by the activated ErbB-2 oncogene (Yu
et al., 2001). This was demonstrated by crossing cyclin D12/2
mice with a breast cancer-prone transgenic strain expressing
the activated ErbB-2 oncogene driven by the MMTV promoter.
Having shown that the kinase activity of cyclin D1-CDK4/6 com-
plexes is dispensable for mammary development (Figure 3), we
asked whether the kinase activity is required for ErbB-2-driven
breast tumorigenesis. To answer this question, we crossed
cyclin D1KE/KE mice with MMTV-ErbB-2 animals and analyzed
the incidence of tumor formation in the resulting cyclin D1+/+;
MMTV-ErbB-2 and cyclin D1KE/KE;MMTV-ErbB-2 females. As
expected, cyclin D1+/+;MMTV-ErbB-2 mice began to develop
mammary tumors at approximately 6 months of age, and virtu-
ally all of these mice had developed tumors by 12 months of
age, similar to previously reported results (Muller et al., 1988;
Yu et al., 2001). In striking contrast, mice expressing kinase-
deficient cyclin D1 KE-CDK complexes were resistant to
ErbB-2-induced breast cancers (Figure 6A). Importantly, we ver-
ified that this resistancewas not caused by the absence of cyclin
D1 expression (Figure 6B), or by inadequate transgene expres-
sion levels (Figure 6C) in the mammary glands of cyclin D1KE/KE;
MMTV-ErbB-2 mice. These observations strongly suggest that
the kinase activity of cyclin D1-CDK complexes is critically re-
quired for ErbB-2-driven breast tumorigenesis.
The work presented here documents a differential require-
ment for cyclin D1-associated kinase activity in development
versus in tumorigenesis. In our analyses, we utilized mice ex-
pressing a cyclin D1 mutant that has been previously shown
to be deficient in CDK4/6 activation. As is always the case
with kinase-deficient mutants, we cannot formally exclude the
presence of very low, residual kinase activity of this mutant in
vivo. However, even if the cyclin D1 KE protein is not completely
deficient in CDK4/6 activation, our results indicate that greatly
reduced kinase activity has a dramatically different impact on
development versus on tumor formation.
Consistent with this thinking, in the accompanying paper, Yu
et al. (2006) demonstrate that mammary glands lacking CDK4,
cyclin D1’s major catalytic partner in this tissue, develop nor-
mally but are completely resistant to mammary carcinomas ini-
tiated by ErbB-2. Moreover, the presence of cyclin D1-CDK4
complexes is required not only for the initiation of tumors, but
also to sustain tumor cell proliferation. These studies, together
with our observations that the kinase activity of cyclin D1-CDK
complexes is largely dispensable for development of several
compartments, suggests that targeting cyclin D1-associated
kinase activity may be a viable and specific strategy for clinical
treatment of certain breast tumors.C: PCR amplification products from wild-type (+/+) and cyclin D1KE/KE (KE/KE) animals were subcloned and sequenced to demonstrate the presence of the
K112E mutation; representative traces are shown.
D:Western blot analysis of cyclin D1 levels in the indicated organs of wild-type (WT) and cyclin D1KE/KE (KE) mice. Probing for actin was used to ensure equal
loading.
E and F:Western blot analyses of lysates prepared from wild-type (WT), cyclin D1KE/KE (KE), or cyclin D12/2 (KO) day 13.5 embryos. Immunoblots were probed
with the indicated antibodies. Probing for tubulin was used to ensure equal loading.17
A R T I C L EFigure 2. Analyses of the cyclin D1KE/KE retinas
A: Appearance of the retinas in 2-month-old wild-type (WT), cyclin D1KE/KE (KE), and cyclin D12/2 (KO) mice. Histological sections were stained with hematox-
ylin and eosin. GL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. Scale bar, 50 mm.
B: Electroretinographic testing of 3-month-old wild-type (WT; n = 3), cyclin D1KE/KE (KE; n = 3), and cyclin D12/2 (KO; n = 2) mice. The mean amplitudes of the A
and Bwaves generated in response to a flash of light are shown. Error bars represent standard deviation. The results obtained for WT and KOmice are virtually
identical to previously reported results (Sicinski et al., 1995).
C:Western blot analyses of retina lysates. Neural retinas were microdissected from 1-day-old pups. Immunoblots were probed with the indicated antibodies.
D: Association of CDK4 with cyclin D1 and p27 in wild-type (WT), cyclin D1KE/KE (KE), and cyclin D12/2 (KO) retinas. CDK4 was immunoprecipitated from the
retina lysates, and the immunoblots were probed with the indicated antibodies. Although less CDK4 was immunoprecipitated from the KE retinas, likely
due to reduced expression, the relative amounts of cyclin D1 and p27 bound to CDK4 are very similar to those seen in WT retinas. Note that there is no
p27 bound to CDK4 in the absence of cyclin D1 (KO samples).
E: CDK2-associated kinase activity was determined by immunoprecipitating CDK2 from retina lysates of the indicated genotypes and performing in vitro
kinase assays using histone H1 (HH1) as a substrate. For control, samples were immunoprecipitated with isotype matched rabbit anti-mouse (RaM) IgG.
F: Phosphorylation of pRBwas studied by subjecting retina lysates to immunoblot analyses with an antibody that recognizes all of the phospho-forms of pRB, or
an antibody specific to phospho-serine 780 (pS780).18 CANCER CELL JANUARY 2006
A R T I C L EExperimental procedures
Engineering of cyclin D1KE/KE mice
All animal experiments performed herein were approved by and conform to
the standards of the Institutional Animal Care and Use Committees at the
Dana-Farber Cancer Institute, Harvard Medical School, and Tufts-New En-
gland Medical Center.
Genomic fragments of the cyclin D1 locus have been described (Sicinski
et al., 1995). A point mutation (50-TAAGAT-30 to 50-TGAGAT-30) changing
K112 to E was generated by PCR and introduced into a targeting vector
extending w4.4 kbp upstream to the XbaI site and w4.2 kbp downstream
to the MfeI site. The vector also contained a closely linked silent muta-
tion (50-CACCTG-30 to 50-CACGTG-30) creating a novel PmlI site. A LoxP-
neoR-LoxP drug cassette was inserted at the EcoRI site. Linearized targeting
vector was electroporated into J1 ES cells, andG418-resistant ES cell clones
were selected, expanded, and frozen essentially as described previously
(Jacks et al., 1992; Sicinski et al., 1995). DNA from ES clones was screened
for homologous recombination from both ends by Southern blot using exter-
nal probes P1 and P2 (Figure 1A). Chimeric mice were generated essentially
as described previously (Jacks et al., 1992; Sicinski et al., 1995). A series of
matings to C57BL/6 wild-type, nestin-cre (Trumpp et al., 1999), and C57BL/6
wild-type mice was performed to effect the excision of the drug cassette and
remove the cre transgene. Resulting heterozygotes were mated to homozy-
gosity. PCR (forward primer, 50-TGTGAGGAGCAGAAGTGCGAA-30; back-
ward primer, 50-AGATCTGTCCATGGATGGCTG-30) followed by digestion
with PmlI was used to genotype the mice. PCR products from homozygote
mutant mice were subcloned (TOPO-TA, Invitrogen) and sequenced to con-
firm the presence of the mutation.
Western blotting, immunoprecipitation, and in vitro kinase assays
For Western blotting, IP-Westerns, and IP-kinase assays, tissues were dis-
sected and either lysed immediately or snap frozen and stored at 280ºC
for later use. Tissues were subjected to Dounce homogenization in ELB,
and Western blotting was performed essentially as described previously
(Baker et al., 2005). For IP-Westerns and IP-kinase assays, tissues were
subjected to Dounce homogenization in D-IP buffer followed by immunopre-
cipitation and Western blotting or immunoprecipitation followed by in vitro
kinase assay essentially as described previously (Baker et al., 2005).
Figure 3. Normal mammary epithelial lobuloalveolar development in cyclin
D1KE/KE females
Whole-mount appearance (A) and H&E-stained sections (B) of mammary
glands fromwild-type (WT) and cyclin D1KE/KE (KE) females on the day of de-
livery of pups. In A, the mammary epithelial tree was visualized by carmine
red staining. Arrowheads in B indicate alveoli filled with milk proteins. Scale
bar in A, 0.5 cm. Scale bar in B, 100 mm.CANCER CELL JANUARY 2006Antibodies used in this study included anti-cyclin D1 (72-13G, Santa Cruz),
anti-cyclin D2 (M-20, Santa Cruz), anti-cyclin D3 (C-16, Santa Cruz), anti-
CDK4 (C-22, Santa Cruz or Ab-2, Neomarkers), anti-CDK6 (C21, Santa
Cruz or Ab-3, Neomarkers), anti-cyclin E (M-20, Santa Cruz), anti-
CDK2 (M2, Santa Cruz), anti-p27 (anti-Kip1/p27, Transduction Laboratories),
anti-cyclin A (CY-A1, Sigma), anti-pRb (Ab-245, Pharmingen), anti-pRb
phospho-S780 (Cell Signaling Technologies), anti-actin (C-2, Santa Cruz),
and anti-a-tubulin (AB-1, Oncogene Research Products). Immunoprecipita-
tions were carried out using agarose-conjugated anti-CDK4 (C-22, Santa
Cruz) and anti-CDK2 (M-2, Santa Cruz) bound to protein A-Sepharose (Amer-
sham Biosciences) for 1 hr before addition of protein lysates. Immunoblot
Figure 4. Retarded growth and pathological reflexes in cyclin D1KE/KE mice
A:Wild-type (WT) and cyclin D1KE/KE (KE)mice are shownbeing lifted by their
tails. The cyclin D1KE/KE mouse is smaller and demonstrates a pathological
‘‘leg-clasping’’ reflex.
B:Male (M) and female (F) wild-type (WT) and cyclin D1KE/KE (KE) mice were
weighed at the indicated times. Each point represents the average weight
of the animals in a given group (n = 4 for WT and KE males, n = 2 for WT fe-
males, n = 3 for KE females). Error bars denote standard deviation.
C:Mean body weights of 18-day-old wild-type (WT; n = 4) and cyclin D1KE/KE
(KE; n = 4)malemice. Values for heterozygouscyclin D1KE/+males (HET; n = 8)
are also shown. Error bars denote standard deviation.19
A R T I C L EFigure 5. Impaired cerebellar development in
cyclin D1KE/KE;cyclin D22/2mice
A: Abnormal cerebellar development in cyclin
D1KE/KE;cyclin D22/2 compoundmutant animals.
Sagittal sections of cerebella collected from
17-day-old mice were stained with hematoxylin
and eosin. The cerebella of cyclin D1KE/KE;cyclin
D22/2 animals have reduced numbers of folia
and display profoundly reduced cellularity in
the inner granular layer (IGL). The cerebella of
a cyclin D12/2;cyclin D22/2 compound mutant
animal and its control littermates are shown for
comparison. Scale bar, 0.5 mm.
B: Higher magnification of A showing abnormal
layering of Purkinje cells (arrow) and severely hy-
poplastic IGL in the cyclin D1KE/KE;cyclin D22/2
cerebellum. Scale bar, 50 mm.analysis was carried out using horseradish peroxidase-conjugated donkey
anti-rabbit or donkey anti-mouse (Jackson ImmunoResearch Laboratories).
Cerebellar, retinal, and mammary gland histology
and retinal biochemistry
Tissues were fixed in Bouin’s fixative (Sigma) and were processed as de-
scribed (Sicinski et al., 1995). To obtain neural retinas for biochemical ana-
lyses, eyes were dissected from postnatal day 1 pups and placed in PBS.
The neural retinas were microdissected away from the lens, snap frozen,
and stored at 280ºC until use.
Electroretinographic analyses
Electroretinogram analysis was carried out as described previously (Sicinski
et al., 1995).
Mammary gland whole mounts
Inguinal mammary glands were dissected and spread onto glass slides.
Staining was performed as described previously (Wang et al., 1990). Briefly,
samples were fixed in a 1:3 mixture of glacial acetic acid:ethanol, hydrated,20and stained overnight in 0.2% carmine (Sigma) and 0.5% AlK(SO4)2, dehy-
drated in graded ethanol solutions, cleared in toluene, and stored in methyl-
salicylate.
Tumor experiments
MMTV-ErbB-2mice (strain TG. NK; Muller et al., 1988) were purchased from
the Charles River Laboratories. cyclin D1KE/+ animals were crossed with
MMTV-ErbB-2 animals to eventually generate cyclin D1KE/KE;MMTV-ErbB-
2 (n = 31) and cyclin D1+/+;MMTV-ErbB-2 (n = 22) females. Females were
monitored biweekly for tumor formation by palpation. Adenocarcinomas aris-
ing in cyclin D1+/+;MMTV-ErbB-2 females were excised and confirmed histo-
logically.
RT-PCR
First strand synthesis was carried out using the iScript kit (BioRad) according
to themanufacturer’s instruction. PCRwas carried out using primers specific
for the MMTV-ErbB-2 transgene as described previously (Yu et al., 2001).CANCER CELL JANUARY 2006
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